Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 7:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Amyloid Beta Protein Clear all
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Hypertension, Intracranial Pulsatility and Brain Amyloid-beta Accumulation in Older Adults (HIPAC Trial)

NCT03354143
View directory record Official record
Conditions
Hypertension
Interventions
Standard Care, Intensive Treatment
Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
55 Years to 79 Years
Enrollment
85 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2024
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 1, 2025 · Synced Sep 28, 2026, 7:12 PM EDT
Completed Phase 4 Interventional Results available

Magnetic Resonance Spectroscopy Study of Memantine in Alzheimer's Disease

NCT00551161
View directory record Official record
Conditions
Alzheimer Disease
Interventions
memantine
Drug
Lead sponsor
Northwell Health
Other
Eligibility
50 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Manhasset, New York
Source: ClinicalTrials.gov public record
Updated Jan 27, 2014 · Synced Sep 28, 2026, 7:12 PM EDT
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

DUVAX: A Phase 1 Alzheimer's Vaccine Study Targeting Amyloid-Beta and Tau

NCT07142278
View directory record Official record
Conditions
Alzheimer Disease, Alzheimer Disease (AD), Preclinical Alzheimer's Disease
Interventions
DUVAX 200 µg, DUVAX 400 µg, Placebo (Adjuvant only)
Biological
Lead sponsor
Nuravax, Inc.
Industry
Eligibility
40 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Miami Lakes, Florida
Source: ClinicalTrials.gov public record
Updated Aug 23, 2026 · Synced Sep 28, 2026, 7:12 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Biomarker Study of Solanezumab in Patients With and Without Alzheimer's

NCT01148498
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
solanezumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 90 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 24, 2012 · Synced Sep 28, 2026, 7:12 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Modulation of CSF Amyloid-beta Concentrations Via Behavioral Sleep Deprivation and Pharmacological Sleep Induction

NCT02063217
View directory record Official record
Conditions
Amyloid-beta
Interventions
Sodium Oxybate, Sleep deprivation
Drug · Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 60 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 25, 2018 · Synced Sep 28, 2026, 7:12 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Relaxation vs. Retreat Study

NCT01857830
View directory record Official record
Conditions
Stress, Ageing, Wellbeing
Interventions
Meditation Retreat, Active Comparator Relaxation Group
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
30 Years to 60 Years · Female only
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Carlsbad, California
Source: ClinicalTrials.gov public record
Updated Aug 20, 2013 · Synced Sep 28, 2026, 7:12 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Use of [123I] AV39 and SPECT Imaging as a Marker of Protein Disposition in Subjects With Alzheimer Disease Compared to Healthy Subjects

NCT00439010
View directory record Official record
Conditions
Alzheimers Disease
Interventions
[123I] AV 39
Drug
Lead sponsor
Molecular NeuroImaging
Other
Eligibility
50 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 23, 2008 · Synced Sep 28, 2026, 7:12 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Assessing the Influence of Habitual Beef Intake on Key Molecular Markers of Brain Health

NCT07623785
View directory record Official record
Conditions
Healthy Aging, Brain Health, Cardiometabolic Health, Normal Aging, Cognitive Decline Prevention in Robust Older Adults
Interventions
Lean Beef, Non-Beef Control
Other
Lead sponsor
South Dakota State University
Other
Eligibility
65 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Brookings, South Dakota
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Sep 28, 2026, 7:12 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Dose-ranging Safety and Tolerability Study in Subjects ≥60 Years of Age

NCT02576639
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
CNP520, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
60 Years to 80 Years
Enrollment
124 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
4
States / cities
Glendale, California • Long Beach, California • Miami, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2017 · Synced Sep 28, 2026, 7:12 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Sleep Quality and Amyloid-Beta Kinetics

NCT03077620
View directory record Official record
Conditions
Amyloid-beta
Interventions
Suvorexant, Placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
45 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 16, 2022 · Synced Sep 28, 2026, 7:12 PM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Alzheimer's Plasma Extension

NCT06416072
View directory record Official record
Conditions
Preclinical Alzheimer's Disease, Alzheimer's Disease (AD)
Interventions
NAV4694
Radiation
Lead sponsor
University of Southern California
Other
Eligibility
55 Years to 80 Years
Enrollment
3,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
56
States / cities
Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 48 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Sep 28, 2026, 7:12 PM EDT
Completed Phase 1 Interventional

Study to Evaluate the Effect of CT1812 Treatment on Amyloid Beta Oligomer Displacement Into CSF in Subjects With Mild to Moderate Alzheimer's Disease

NCT03522129
View directory record Official record
Conditions
Alzheimer Disease
Interventions
CT1812, Placebo
Drug
Lead sponsor
Cognition Therapeutics
Industry
Eligibility
50 Years to 80 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
2
States / cities
New York, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 11, 2022 · Synced Sep 28, 2026, 7:12 PM EDT
Completed Phase 2Phase 3 Interventional Results available

A Study to Evaluate Albumin and Immunoglobulin in Alzheimer's Disease

NCT01561053
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Albumin 5%, Albumin 20%, Immunoglobulin
Biological
Lead sponsor
Instituto Grifols, S.A.
Industry
Eligibility
55 Years to 85 Years
Enrollment
347 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
22
States / cities
Sacramento, California • Denver, Colorado • Washington D.C., District of Columbia + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2019 · Synced Sep 28, 2026, 7:12 PM EDT
Completed Phase 2 Interventional

Citalopram as a Posterior Cortical Protective Therapy in Parkinson Disease

NCT04497168
View directory record Official record
Conditions
Parkinson Disease
Interventions
Citalopram 20mg, Placebo
Drug
Lead sponsor
University of Michigan
Other
Eligibility
65 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 15, 2026 · Synced Sep 28, 2026, 7:12 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Single Photon Emission Computed Tomography (SPECT) Imaging Study to Develop a Biomarker for Alzheimer's Disease

NCT00886951
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
I123MNI388/I123MNI390
Drug
Lead sponsor
Institute for Neurodegenerative Disorders
Other
Eligibility
50 Years and older
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 2, 2019 · Synced Sep 28, 2026, 7:12 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Evaluation of [123I] MNI-308 and SPECT as a Marker of Beta-amyloid Protein Deposition in AD Subjects Compared to HC

NCT00544453
View directory record Official record
Conditions
Alzheimer Disease
Interventions
[123I] MNI-308
Drug
Lead sponsor
Molecular NeuroImaging
Other
Eligibility
50 Years and older
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 20, 2009 · Synced Sep 28, 2026, 7:12 PM EDT
Terminated Early Phase 1 Interventional Accepts healthy volunteers

Safety and Efficacy of Positron Emission Tomography Imaging With MNI-513

NCT01000870
View directory record Official record
Conditions
Alzheimer Disease
Interventions
MNI-513-01
Drug
Lead sponsor
Institute for Neurodegenerative Disorders
Other
Eligibility
55 Years and older
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 5, 2010 · Synced Sep 28, 2026, 7:12 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Phase II Study of Florbetaben (BAY94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid.

NCT00928304
View directory record Official record
Conditions
Down Syndrome, Amyloid Beta-protein
Interventions
Florbetaben (BAY94-9172)
Drug
Lead sponsor
Lantheus Biosciences Ltd.
Industry
Eligibility
21 Years and older
Enrollment
109 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
2
States / cities
Sun City, Arizona • New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 4, 2014 · Synced Sep 28, 2026, 7:12 PM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Curcumin and Retinal Study

NCT05774704
View directory record Official record
Conditions
Bioavailability, Gut Microbiome, Safety
Interventions
Low curcumin group, High curcumin group
Drug
Lead sponsor
Texas Tech University Health Sciences Center
Other
Eligibility
40 Years to 89 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Lubbock, Texas
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Sep 28, 2026, 7:12 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Healthy Subjects to Assess the Effect of LY450139 on Amyloid Beta Peptide Production Rate and or Dose Response.

NCT00765115
View directory record Official record
Conditions
Alzheimer Disease
Interventions
LY450139, placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
21 Years to 50 Years · Male only
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 1, 2008 · Synced Sep 28, 2026, 7:12 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Escitalopram Effects on CSF Amyloid Beta

NCT02161458
View directory record Official record
Conditions
Amyloid Beta Protein
Interventions
Escitalopram 20mg for 2 weeks, Escitalopram 20mg for 8 weeks, Escitalopram 30mg for 8 weeks, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
60 Years to 85 Years
Enrollment
98 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2019
U.S. locations
2
States / cities
St Louis, Missouri • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 8, 2020 · Synced Sep 28, 2026, 7:12 PM EDT
Recruiting Phase 2 Interventional

A Phase 2 Efficacy and Safety Study of GAL-101, 2% Ophthalmic Solution in Non-foveal Geographic Atrophy Secondary to Non-neovascular AMD

NCT06659549
View directory record Official record
Conditions
Geographic Atrophy of the Macula
Interventions
GAL-101, Placebo
Drug
Lead sponsor
Galimedix Therapeutics Inc
Industry
Eligibility
55 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
3
States / cities
Beverly Hills, California • Walnut Creek, California • Hagerstown, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Sep 28, 2026, 7:12 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

The Effect of Short-Term Statins and NSAIDs on Levels of Beta-Amyloid, a Protein Associated With Alzheimer's Disease

NCT00046358
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Lovostatin, Ibuprofen
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
Not listed
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 28, 2026, 7:12 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Safety and Efficacy of Positron Emission Tomography (PET) Imaging With MNI-558

NCT01217021
View directory record Official record
Conditions
Alzheimer Disease
Interventions
[18F] MNI-558
Drug
Lead sponsor
Institute for Neurodegenerative Disorders
Other
Eligibility
55 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 24, 2011 · Synced Sep 28, 2026, 7:12 PM EDT